News Categories
Record Year For Australia's Medical Cannabis Approvals

Australia’s Therapeutic Goods Administration approved 57,781 SAS (Special Access Scheme) Category B applications for unapproved medicinal cannabis products in 2020.
It was a huge year given the TGA has only approved 85,000 SAS Category B applications since this medicinal cannabis pathway was established way back in 1992. Here’s how 2020 shaped up for approvals for each month according to the TGA.
- January – 3148
- February – 3568
- March – 3926
- April – 3378
- May – 4133
- June – 4630
- July – 5564
- August – 5270
- September – 6206
- October – 5972
- November – 6356
- December – 5630
It should be noted approval numbers don’t reflect the number of patients receiving these medicines under the SAS as multiple approvals can be attributed to a single patient, and some patients may discontinue use of medicinal cannabis products.
While the uptick in approvals is encouraging, something concerning is a reported continuing lack of supply and exorbitant costs associated with prescription products. MCUA president Deb Lynch says most of the product grown in Australia is being exported, contributing to supply issues.
Others say Christmas demand has delayed supply, with some products completely sold out. And it’s not just a matter of patients switching to another strain or type of product as prescriptions are product-specific. To make the switch, a new prescription needs to be acquired along with a new approval from the TGA.
Looking ahead, it will be interesting to see how the TGA’s decision to make certain CBD medicines available without a prescription from February 1 will impact on the number of approvals in 2021. However, while low-dose cannabidiol will be available under Schedule 3 (Pharmacist Only) from February, it remains to be seen if any products will be listed on the Australian Register of Therapeutic Goods (ARTG) from the get-go; which is a requirement. Also, the maximum recommended daily dose will be 150mg and many patients prescribed cannabidiol are taking much higher doses, so may continue to need to access prescription medicines.
Still, this is all progress; although for Australians who are impacted by supply and cost issues, that’s little comfort and further reforms can’t come soon enough.
420 Intel is Your Source for Marijuana News
420 Intel is the leading source for cannabis news from around the world. Get the latest updates on cannabis legalization, politics and technology, as well as developments in medical and recreational marijuana news. Our commitment is to bring you the most important cannabis news stories every day of the week.
At 420 Intel we understand that effective marijuana industry news coverage is a constant endeavor. Every day stories develop regarding cannabis legalization, technological developments, and the medicinal benefits of marijuana use. Each new development carries the potential to impact the marijuana industry regionally, nationally, and internationally. 420 Intel is the marijuana industry news outlet that will keep you up to date on these developments and how they impact the world around you.
With the marijuana industry constantly evolving, you need a cannabis news outlet to keep you abreast of the pertinent information. At 420 Intel, we cover marijuana legalization news throughout the world, offer reliable information for cannabis business owners, detail technological advances that impact the marijuana industry, cover marijuana rallies from across the globe, and everything in between.
You can get 420 Intel news delivered directly to your inbox by signing up for our daily marijuana news, ensuring you’re always kept up to date on the ever-changing cannabis industry. To stay even better informed about marijuana legalization news follow us on Twitter, Facebook and LinkedIn.